Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1947 3
1948 3
1949 2
1951 35
1952 80
1953 87
1954 97
1955 107
1956 108
1957 84
1958 77
1959 88
1960 75
1961 95
1962 116
1963 220
1964 273
1965 155
1966 199
1967 241
1968 279
1969 267
1970 281
1971 318
1972 342
1973 315
1974 372
1975 322
1976 267
1977 296
1978 270
1979 262
1980 238
1981 193
1982 225
1983 259
1984 258
1985 293
1986 254
1987 303
1988 310
1989 354
1990 545
1991 709
1992 827
1993 816
1994 857
1995 1005
1996 1039
1997 1091
1998 1101
1999 1139
2000 1259
2001 1182
2002 1355
2003 1389
2004 1403
2005 1557
2006 1642
2007 1768
2008 1683
2009 1668
2010 1868
2011 1901
2012 2066
2013 2135
2014 2246
2015 2356
2016 2208
2017 2118
2018 2048
2019 2249
2020 2364
2021 2615
2022 2594
2023 2469
2024 742

Text availability

Article attribute

Article type

Publication date

Search Results

59,052 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean non hodgkin s lymphoma b cell (97,908 results)?
B Cell Lymphoma.
Meng X, Min Q, Wang JY. Meng X, et al. Adv Exp Med Biol. 2020;1254:161-181. doi: 10.1007/978-981-15-3532-1_12. Adv Exp Med Biol. 2020. PMID: 32323276 Review.
B cell development and activation are accompanied by dynamic genetic alterations including V(D)J rearrangements and immunoglobulin-gene somatic hypermutation and class-switch recombination. ...In fact, B cell lymphoma accounts for 95% of the lym …
B cell development and activation are accompanied by dynamic genetic alterations including V(D)J rearrangements and immunoglob …
B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy.
Jiang L, Li N. Jiang L, et al. Angiogenesis. 2020 Nov;23(4):515-529. doi: 10.1007/s10456-020-09729-7. Epub 2020 May 25. Angiogenesis. 2020. PMID: 32451774 Review.
While angiogenesis in solid tumors has been well characterized, a large body of investigation is devoted to clarify the impact of angiogenesis on lymphoma development. B-cell non-Hodgkin lymphoma (B-NHL) is the most common lymphoid malign …
While angiogenesis in solid tumors has been well characterized, a large body of investigation is devoted to clarify the impact of angiogenes …
miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma.
Fuertes T, Ramiro AR, de Yebenes VG. Fuertes T, et al. Trends Immunol. 2020 Oct;41(10):932-947. doi: 10.1016/j.it.2020.08.006. Epub 2020 Sep 1. Trends Immunol. 2020. PMID: 32888820 Free article. Review.
Non-Hodgkin lymphoma (NHL) is a diverse class of hematological cancers, many of which arise from germinal center (GC)-experienced B cells. ...Here, we discuss the scientific rationale for miRNA-based therapeutics in B cell neoplasias and review …
Non-Hodgkin lymphoma (NHL) is a diverse class of hematological cancers, many of which arise from germinal center (GC)-e …
B-cell neoplasms and Hodgkin lymphoma in the spleen.
Geyer JT, Prakash S, Orazi A. Geyer JT, et al. Semin Diagn Pathol. 2021 Mar;38(2):125-134. doi: 10.1053/j.semdp.2020.08.002. Epub 2020 Aug 10. Semin Diagn Pathol. 2021. PMID: 32839024 Review.
B-cell lymphoma of spleen may be primary (most commonly splenic diffuse large B-cell lymphoma) or secondary (typically low-grade non-Hodgkin lymphoma). ...This review article describes the clinicopathologic characteri …
B-cell lymphoma of spleen may be primary (most commonly splenic diffuse large B-cell lymphoma) or …
Breakthrough therapies in B-cell non-Hodgkin lymphoma.
Cheah CY, Fowler NH, Wang ML. Cheah CY, et al. Ann Oncol. 2016 May;27(5):778-87. doi: 10.1093/annonc/mdw029. Epub 2016 Jan 22. Ann Oncol. 2016. PMID: 26802148 Free article. Review.
The last 5 years have seen significant advances in our understanding of the molecular pathogenesis of B-cell lymphomas. This has led to the emergence of a large number of new therapeutic agents exploiting precise aspects of the tumor cell's signaling pathways, surfa …
The last 5 years have seen significant advances in our understanding of the molecular pathogenesis of B-cell lymphomas. This h …
Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.
Ryan RJH, Wilcox RA. Ryan RJH, et al. Hematol Oncol Clin North Am. 2019 Aug;33(4):553-574. doi: 10.1016/j.hoc.2019.04.003. Epub 2019 May 18. Hematol Oncol Clin North Am. 2019. PMID: 31229154 Free PMC article. Review.
Here, we review the principles of diagnostic classification for non-Hodgkin lymphomas, summarize the characteristic features of major entities, and place recent biological and molecular findings in the context of principles that are applicable across the spectrum of …
Here, we review the principles of diagnostic classification for non-Hodgkin lymphomas, summarize the characteristic features o …
Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma.
Yang S, Li JY, Xu W. Yang S, et al. Crit Rev Oncol Hematol. 2014 Aug;91(2):113-22. doi: 10.1016/j.critrevonc.2014.02.004. Epub 2014 Feb 23. Crit Rev Oncol Hematol. 2014. PMID: 24629840 Review.
B-cell activating factor (BAFF), as a member of the tumor necrosis factor (TNF) ligand family, plays important roles in B-cell homeostasis, tolerance, and malignancy. ...BAFF-R as the main BAFF receptor is expressed mainly on B-cells. Aberrant BAFF exp …
B-cell activating factor (BAFF), as a member of the tumor necrosis factor (TNF) ligand family, plays important roles in B …
Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Makita S, Yoshimura K, Tobinai K. Makita S, et al. Cancer Sci. 2017 Jun;108(6):1109-1118. doi: 10.1111/cas.13239. Epub 2017 May 25. Cancer Sci. 2017. PMID: 28301076 Free PMC article. Review.
B-cell non-Hodgkin lymphoma (B-NHL) is the most frequent hematological malignancy. ...Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is expected to be an effective adoptive cell treatment and has the potential to overcome the chemorefr …
B-cell non-Hodgkin lymphoma (B-NHL) is the most frequent hematological malignancy. ...Anti-CD19 chimeric …
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies.
Burt R, Warcel D, Fielding AK. Burt R, et al. Hum Vaccin Immunother. 2019;15(3):594-602. doi: 10.1080/21645515.2018.1540828. Epub 2018 Nov 20. Hum Vaccin Immunother. 2019. PMID: 30380973 Free PMC article. Review.
Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell Non-Hodgkin's Lymphoma including in patients who are refractory to chemotherapy. ...We compare and contrast it to ot …
Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell …
B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma.
Jacobsen E, Freedman A. Jacobsen E, et al. Lancet Oncol. 2004 Dec;5(12):711-7. doi: 10.1016/S1470-2045(04)01646-8. Lancet Oncol. 2004. PMID: 15581541 Review.
Autologous stem-cell transplantation is a common therapy for B-cell non-Hodgkin lymphoma. However, a concern with the procedure is the potential of malignant cells to reinfuse with the stem-cell graft. ...
Autologous stem-cell transplantation is a common therapy for B-cell non-Hodgkin lymphoma. However, a conc …
59,052 results
You have reached the last available page of results. Please see the User Guide for more information.